TURKU, 16-3-2015 — /EuropaWire/ — Biotie Therapies Corp. (“Biotie” or the “Company”) has conveyed Biotie shares held as treasury shares, that were issued on 17 December 2014, pursuant to the Equity Incentive Plan 2011 (the “Plan”) as follows: Shares conveyed … Read the full press release
Posted in Business, Financial, Finland, Healthcare, Management, Pharma & Biotech
Tagged Biotie Therapies Corp, Equity Incentive Plan 2011, treasury shares
Turku, Finland, 25-7-2014 — /EuropaWire/ — Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with … Read the full press release
19-8-2013 — /EuropaWire/ — Company Highlights April – June 2013 Biotie obtained an exclusive option to acquire Neurelis, Inc., a private specialty pharmaceutical company based in San Diego, CA, focused on developing products for epilepsy and other disorders of the central nervous … Read the full press release
Posted in Business, Financial, Finland, Healthcare, Investment, Pharma & Biotech
Tagged Alzheimer's disease, Biotie, Biotie Therapies Corp, BTT-1023, cognitive disorders, drugs for neurodegenerative and psychiatric disorders, fibrotic liver disease, Lundbeck A/S, nalmefene, nepicastat, Neurelis, Parkinson's disease, post-traumatic stress disorder, SELINCRO, SYN120, The National Institute on Drug Abuse, Timo Veromaa, Tozadenant, VAP-1 antibody, Virve Nurmi
Turku, 30-5-2013 — /europawire.eu/ — Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment … Read the full press release
Posted in Finland, Healthcare, Pharma & Biotech, United Kingdom
Tagged Biotie, Biotie Therapies Corp, detoxification, H.Lundbeck A/S, high drinking risk level, nalmefene, SELINCRO, Timo Veromaa, Turku
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
